# Iambic Therapeutics **Source:** https://geo.sig.ai/brands/iambic-therapeutics **Vertical:** Healthcare Tech **Subcategory:** AI Drug Discovery **Tier:** Challenger **Website:** iambic.ai **Last Updated:** 2026-04-14 ## Summary AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego. ## Company Overview Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications. ## Frequently Asked Questions ### What is Iambic's AI platform? Combines AI and physics-based modeling with Enchant (multimodal transformer) and NeuralPLexer (protein structure predictor) for small-molecule drug discovery. ### What is the Takeda deal? Multi-year collaboration (Feb 2026) for oncology, inflammation, and GI drugs with milestone payments exceeding $1.7B. ### What is IAM1363? Lead brain-penetrant HER2 inhibitor in Phase 1/1b for oncology. ### How much has Iambic raised? $100M+ in November 2025 oversubscribed round, plus prior $153M Series B. ### Is Iambic publicly traded? No, privately held. Named to CNBC 2025 Disruptor 50. ### What diseases does Iambic Therapeutics focus on? Iambic focuses on oncology as its primary therapeutic area, with additional programs in inflammation and gastrointestinal diseases covered under its Takeda partnership. Its lead oncology candidate IAM1363 is a brain-penetrant HER2 inhibitor targeting solid tumors with HER2 amplification, including brain metastases where existing HER2 therapies have limited CNS penetration — a significant unmet need in breast and lung cancer. ### What is the NeuralPLexer protein structure prediction model? NeuralPLexer is Iambic's proprietary deep learning model for predicting protein-ligand complex structures — how a small molecule drug physically interacts with its protein target. Unlike AlphaFold (which predicts protein structures alone), NeuralPLexer predicts the full interaction complex including molecular flexibility, enabling Iambic to design molecules optimized for binding affinity and selectivity before synthesis. The model was published in Nature Methods and demonstrated superior accuracy to competing methods on benchmark datasets. ### How does Iambic's AI-to-clinic timeline compare to traditional drug discovery? Iambic's AI-driven approach compressed the discovery phase for IAM1363 from the typical 4–6 years to approximately 2 years — generating and screening millions of virtual compounds before synthesizing only the highest-probability candidates. The Takeda partnership validates this efficiency at scale: the $1.7B+ deal covers multiple programs across three therapeutic areas, reflecting Takeda's expectation that Iambic's platform can generate clinical candidates across multiple disease areas simultaneously faster than traditional chemistry teams. ## Tags b2b, healthtech, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*